Exact claim · Version 1 · Reviewed 2026-07-23
“Teduglutide can reduce parenteral-support needs in short bowel syndrome.”
A verdict on this wording and scope, not a universal grade for Teduglutide.
01 · Verdict
Supported with scope
Controlled trials and the Gattex label support this outcome in dependent short-bowel-syndrome populations.
- Evidence basis
- Randomized human outcomes
- Scope
- Adults and labeled pediatric populations with short bowel syndrome dependent on parenteral support.
- Category
- Clinical outcomes
02 · Primary record
Check the attached evidence
01Teduglutide reduces parenteral support in short bowel syndromePubMed · Gastroenterology · Randomized trial · 2012
Supports the scoped claim02GATTEX (teduglutide) prescribing informationU.S. Food and Drug Administration · Drug label · 2025
Supports the scoped claim
Supports the scoped claim02GATTEX (teduglutide) prescribing informationU.S. Food and Drug Administration · Drug label · 2025
Supports the scoped claim
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.